Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free SLS Stock Alerts

SELLAS Life Sciences Group (SLS) Financials

SELLAS Life Sciences Group logo
$12.62 -0.14 (-1.10%)
Closing price 04:00 PM Eastern
Extended Trading
$12.52 -0.09 (-0.75%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for SELLAS Life Sciences Group

Annual Income Statements for SELLAS Life Sciences Group

This table shows SELLAS Life Sciences Group's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -64 -18 -24 -41 -28 -17 -21 -41 -37 -31 -27
Consolidated Net Income / (Loss)		 -64 -18 -24 -28 -19 -17 -21 -41 -37 -31 -27
Net Income / (Loss) Continuing Operations		 -39 -18 -24 -28 -19 -17 -21 -41 -37 -31 -27
Total Pre-Tax Income 		-39 -18 -24 -29 -19 -17 -21 -41 -37 -31 -27
Total Operating Income		 -34 -16 -23 -31 -20 -17 -25 -42 -38 -32 -28
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 1.90 7.40 0.90 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 1.90 7.60 1.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.20 0.10 0.00 0.00 0.00
Total Operating Expenses		 34 16 23 31 20 19 33 43 38 32 28
Selling, General & Admin Expense		 11 4.59 15 13 9.92 9.60 11 13 14 12 12
Research & Development Expense		 24 11 6.07 8.77 7.29 9.28 16 30 24 19 16
Total Other Income / (Expense), net		 -4.37 -1.69 -0.46 2.04 0.67 0.21 4.36 0.65 0.53 0.63 1.41
Interest & Investment Income		 -0.76 - - - - - - - 0.53 0.63 1.41
Basic Earnings per Share		 ($8.23) ($18.66) ($10.44) ($157.72) ($10.92) ($2.11) ($1.34) ($2.13) ($1.34) ($0.50) ($0.25)
Weighted Average Basic Shares Outstanding		 7.76M 947.40K 2.34M 261.54K 2.56M 7.98M 15.48M 19.40M 27.78M 61.20M 109.05M
Diluted Earnings per Share		 ($8.23) ($18.66) ($10.44) ($157.72) ($10.92) ($2.11) ($1.34) ($2.13) ($1.34) ($0.50) ($0.25)
Weighted Average Diluted Shares Outstanding		 7.76M 947.40K 2.34M 261.54K 2.56M 7.98M 15.48M 19.40M 27.78M 61.20M 109.05M
Weighted Average Basic & Diluted Shares Outstanding		 7.76M 947.40K 2.34M 261.54K 2.56M 7.98M 15.91M 28.30M 56.27M 90.85M 179.58M

Quarterly Income Statements for SELLAS Life Sciences Group

This table shows SELLAS Life Sciences Group's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -9.27 -8.14 -9.57 -7.47 -7.11 -6.74 -5.81 -6.60 -6.79 -7.66 -8.41
Consolidated Net Income / (Loss)		 -9.27 -8.14 -9.57 -7.47 -7.11 -6.74 -5.81 -6.60 -6.79 -7.66 -8.41
Net Income / (Loss) Continuing Operations		 -9.27 -8.14 -9.57 -7.47 -7.11 -6.74 -5.81 -6.60 -6.79 -7.66 -8.41
Total Pre-Tax Income 		-9.27 -8.14 -9.57 -7.47 -7.11 -6.74 -5.81 -6.60 -6.79 -7.66 -8.41
Total Operating Income		 -9.36 -8.18 -9.65 -7.62 -7.33 -6.92 -6.06 -6.87 -7.08 -8.26 -9.25
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 9.36 8.18 9.65 7.62 7.33 6.92 6.06 6.87 7.08 8.26 9.25
Selling, General & Admin Expense		 3.55 3.08 4.53 2.44 2.97 2.48 2.86 3.00 2.87 3.53 4.12
Research & Development Expense		 5.81 5.10 5.11 5.19 4.36 4.44 3.21 3.87 4.22 4.73 5.13
Total Other Income / (Expense), net		 0.09 0.04 0.08 0.15 0.22 0.18 0.25 0.27 0.29 0.60 0.85
Interest & Investment Income		 0.09 - 0.08 0.15 0.22 - 0.25 0.27 0.29 0.60 0.85
Basic Earnings per Share		 ($0.33) ($0.23) ($0.21) ($0.13) ($0.10) ($0.06) ($0.07) ($0.07) ($0.06) ($0.05) ($0.05)
Weighted Average Basic Shares Outstanding		 28.36M 27.78M 44.81M 57.63M 68.25M 61.20M 87.76M 98.56M 108.40M 109.05M 172.48M
Diluted Earnings per Share		 ($0.33) ($0.23) ($0.21) ($0.13) ($0.10) ($0.06) ($0.07) ($0.07) ($0.06) ($0.05) ($0.05)
Weighted Average Diluted Shares Outstanding		 28.36M 27.78M 44.81M 57.63M 68.25M 61.20M 87.76M 98.56M 108.40M 109.05M 172.48M
Weighted Average Basic & Diluted Shares Outstanding		 32.06M 56.27M 57.75M 64.33M 70.38M 90.85M 99.78M 105.30M 142.44M 179.58M 186.03M

Annual Cash Flow Statements for SELLAS Life Sciences Group

This table details how cash moves in and out of SELLAS Life Sciences Group's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 6.08 4.57 6.70 -7.30 1.93 28 -14 -4.23 -15 11 58
Net Cash From Operating Activities		 -48 -12 -11 -30 -18 -10 -26 -24 -31 -35 -28
Net Cash From Continuing Operating Activities		 -39 -12 -11 -30 -18 -10 -26 -24 -31 -35 -28
Net Income / (Loss) Continuing Operations		 -64 -18 -24 -28 -19 -17 -21 -41 -37 -31 -27
Consolidated Net Income / (Loss)		 -39 -18 -24 -28 -19 -17 -21 -41 -37 -31 -27
Amortization Expense		 -0.25 - 0.26 - 0.00 - - - - 0.56 0.60
Non-Cash Adjustments To Reconcile Net Income		 32 4.52 6.46 8.57 2.86 0.77 3.48 11 2.04 1.56 1.96
Changes in Operating Assets and Liabilities, net		 15 1.31 6.07 -11 -1.21 5.57 -8.80 6.11 3.86 -6.65 -4.08
Net Cash From Investing Activities		 10 -0.09 12 0.00 0.00 0.00 0.00 -4.50 -5.50 0.00 0.00
Net Cash From Continuing Investing Activities		 -0.35 -0.09 12 0.00 0.00 0.00 0.00 -4.50 -5.50 0.00 0.00
Net Cash From Financing Activities		 44 17 5.53 23 20 38 12 24 22 47 86
Net Cash From Continuing Financing Activities		 44 17 5.53 23 20 38 12 24 22 47 86
Issuance of Common Equity		 48 - 6.01 22 16 30 9.01 24 22 46 74
Other Financing Activities, net		 0.03 - - 0.00 3.60 8.84 3.07 0.00 -0.02 0.50 12
Cash Interest Received		 0.02 - 0.00 0.19 0.12 0.03 0.01 0.32 0.53 0.63 1.41

Quarterly Cash Flow Statements for SELLAS Life Sciences Group

This table details how cash moves in and out of SELLAS Life Sciences Group's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -9.84 -1.44 16 -9.27 12 -7.15 15 -3.10 19 27 35
Net Cash From Operating Activities		 -6.89 -4.83 -11 -9.68 -7.81 -7.15 -9.07 -7.33 -7.07 -4.92 -8.85
Net Cash From Continuing Operating Activities		 -6.89 -4.85 -11 -9.68 -7.81 -7.22 -9.07 -7.33 -7.07 -4.92 -8.85
Net Income / (Loss) Continuing Operations		 -9.27 -8.14 -9.57 -7.47 -7.11 -6.74 -5.81 -6.60 -6.79 -7.66 -8.41
Consolidated Net Income / (Loss)		 -9.27 -8.14 -9.57 -7.47 -7.11 -6.74 -5.81 -6.60 -6.79 -7.66 -8.41
Amortization Expense		 0.12 - 0.14 - - 0.15 0.15 - - 0.15 0.15
Non-Cash Adjustments To Reconcile Net Income		 0.41 0.84 0.48 0.61 0.11 0.17 0.51 0.80 0.21 0.45 0.80
Changes in Operating Assets and Liabilities, net		 1.84 2.82 -1.81 -2.68 -1.22 -0.80 -3.91 -1.38 -0.93 2.14 -1.39
Net Cash From Investing Activities		 -3.00 - 0.00 - - - 0.00 - - - 0.00
Net Cash From Continuing Investing Activities		 -3.00 - 0.00 - - - 0.00 - - - 0.00
Net Cash From Financing Activities		 0.05 3.39 27 0.41 20 0.01 24 4.23 26 32 44
Net Cash From Continuing Financing Activities		 0.05 3.39 27 0.41 20 0.01 24 4.23 26 32 44
Issuance of Common Equity		 0.05 3.40 27 0.06 20 0.07 23 0.02 22 29 0.07
Other Financing Activities, net		 - -0.02 0.05 0.36 0.16 -0.06 0.50 4.21 4.00 3.38 44
Cash Interest Received		 0.09 0.04 0.08 0.15 0.22 0.18 0.25 0.27 0.29 0.60 0.85

Annual Balance Sheets for SELLAS Life Sciences Group

This table presents SELLAS Life Sciences Group's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 82 6.42 34 17 17 46 26 21 6.22 19 78
Total Current Assets		 54 6.38 13 5.84 8.24 37 23 18 3.17 16 75
Cash & Equivalents		 30 5.96 2.32 5.34 7.28 35 21 17 2.53 14 72
Restricted Cash		 0.40 0.09 10 0.11 0.10 0.10 0.10 0.10 0.10 0.10 0.10
Prepaid Expenses		 1.40 0.33 0.34 0.39 0.56 0.40 1.59 0.53 0.54 2.34 3.32
Plant, Property, & Equipment, net		 0.34 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 28 0.04 20 11 8.37 9.12 3.23 3.19 3.05 3.11 3.13
Goodwill		 5.90 - 1.91 1.91 1.91 1.91 1.91 1.91 1.91 1.91 1.91
Other Noncurrent Operating Assets		 22 0.04 19 9.16 6.45 7.21 1.32 1.27 1.13 1.19 1.22
Total Liabilities & Shareholders' Equity		 82 6.42 34 17 17 46 26 21 6.22 19 78
Total Liabilities		 69 11 31 12 11 18 5.93 16 14 9.97 7.47
Total Current Liabilities		 57 5.76 25 5.97 5.29 12 4.98 16 14 9.51 7.02
Accounts Payable		 1.60 - 12 3.76 3.90 4.66 2.14 3.36 5.64 3.50 2.95
Accrued Expenses		 5.29 4.05 3.20 2.22 1.17 1.91 2.64 6.29 7.65 5.47 3.53
Other Current Liabilities		 40 - 1.30 - 0.22 0.22 0.20 5.87 0.45 0.54 0.54
Total Noncurrent Liabilities		 12 5.66 6.89 5.70 5.23 5.70 0.95 0.58 0.46 0.46 0.46
Other Noncurrent Operating Liabilities		 6.14 - 2.60 5.34 4.96 5.46 0.95 0.58 0.46 0.46 0.46
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 14 -5.00 2.07 5.25 6.09 28 20 4.85 -7.98 9.47 71
Total Preferred & Common Equity		 14 -5.00 2.07 5.25 6.09 28 20 4.85 -7.98 9.47 71
Total Common Equity		 14 -5.00 2.07 5.25 6.09 28 20 4.85 -7.98 9.47 71
Common Stock		 297 25 56 87 107 146 159 185 209 258 346
Retained Earnings		 - -30 -54 -82 -101 -118 -139 -180 -217 -248 -275

Quarterly Balance Sheets for SELLAS Life Sciences Group

This table presents SELLAS Life Sciences Group's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 19 8.09 24 15 27 35 32 52 114
Total Current Assets		 16 5.20 22 12 24 32 29 49 111
Cash & Equivalents		 14 3.97 18 9.15 21 28 25 44 107
Restricted Cash		 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10
Prepaid Expenses		 1.67 1.13 2.99 3.06 2.90 3.48 4.05 4.63 3.97
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 2.99 2.88 2.93 2.82 2.47 2.98 2.86 2.50 3.01
Goodwill		 1.91 1.91 1.91 1.91 1.91 1.91 1.91 1.91 1.91
Other Noncurrent Operating Assets		 1.07 0.97 1.02 0.90 0.56 1.07 0.94 0.59 1.09
Total Liabilities & Shareholders' Equity		 19 8.09 24 15 27 35 32 52 114
Total Liabilities		 14 12 15 12 11 7.20 6.16 5.93 6.77
Total Current Liabilities		 13 12 14 12 11 6.89 6.00 5.93 6.46
Accounts Payable		 3.73 4.34 7.41 6.33 4.55 3.76 3.34 2.31 3.63
Accrued Expenses		 6.24 6.93 6.54 5.18 5.49 2.57 2.08 3.02 2.26
Other Current Liabilities		 3.45 0.47 0.49 0.53 0.58 0.56 0.58 0.60 0.56
Total Noncurrent Liabilities		 0.30 0.18 0.31 0.16 0.00 0.31 0.16 0.00 0.31
Other Noncurrent Operating Liabilities		 0.30 0.18 0.31 0.16 0.00 0.31 0.16 0.00 0.31
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 4.84 -3.83 9.68 2.91 16 28 26 46 107
Total Preferred & Common Equity		 4.84 -3.83 9.68 2.91 16 28 26 46 107
Total Common Equity		 4.84 -3.83 9.68 2.91 16 28 26 46 107
Common Stock		 205 205 236 237 257 282 287 313 391
Retained Earnings		 -200 -209 -227 -234 -241 -254 -261 -267 -283

Annual Metrics And Ratios for SELLAS Life Sciences Group

This table displays calculated financial ratios and metrics derived from SELLAS Life Sciences Group's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 161,906,753.00 217,019,065.00 45,712,912.00 22,026,476.00 4,871,927.00 9,461,978.00 15,885,542.00 20,588,247.00 32,062,258.00 - 142,442,239.00
DEI Adjusted Shares Outstanding		 5,397.00 7,234.00 30,475.00 440,530.00 4,871,927.00 9,461,978.00 15,885,542.00 20,588,247.00 32,062,258.00 - 142,442,239.00
DEI Earnings Per Adjusted Shares Outstanding		 -11,840.28 -2,444.15 -801.61 -93.64 -5.74 -1.78 -1.30 -2.01 -1.16 - -0.19
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -24 -11 -16 -22 -14 -12 -18 -29 -27 -22 -20
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - 332.35% -233.06% -27.93%
Earnings before Interest and Taxes (EBIT)		 -38 -17 -23 -30 -19 -17 -21 -42 -38 -32 -28
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -38 -17 -23 -30 -19 -17 -21 -42 -38 -31 -28
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -16 -14 -20 -21 -13 -5.73 -24 -18 -28 -28 -23
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -6.35 -3.68 0.31 -0.21 -1.28 -7.44 -1.11 -12 -11 -4.52 -1.02
Increase / (Decrease) in Invested Capital		 -8.11 2.67 3.98 -0.51 -1.08 -6.16 6.33 -11 1.77 6.09 3.50
Book Value per Share		 $0.08 ($0.02) $0.05 $0.24 $1.25 $2.96 $1.28 $0.24 ($0.25) $0.13 $0.50
Tangible Book Value per Share		 $0.05 ($0.02) $0.00 $0.15 $0.86 $2.75 $1.16 $0.14 ($0.31) $0.11 $0.48
Total Capital		 18 2.37 13 5.25 6.09 28 20 4.85 -7.98 9.47 71
Total Debt		 4.74 7.37 11 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 5.66 2.61 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -25 1.32 -1.76 -5.45 -7.38 -35 -21 -17 -2.63 -14 -72
Capital Expenditures (CapEx)		 -12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -29 -3.72 -16 -5.59 -4.43 -11 -3.39 -15 -13 -7.17 -3.70
Debt-free Net Working Capital (DFNWC)		 1.29 2.33 -3.11 -0.14 2.95 25 18 2.24 -11 6.82 68
Net Working Capital (NWC)		 -3.45 0.62 -11 -0.14 2.95 25 18 2.24 -11 6.82 68
Net Nonoperating Expense (NNE)		 40 6.49 7.63 5.91 5.26 4.87 2.99 12 11 8.82 7.07
Net Nonoperating Obligations (NNO)		 -20 1.32 -1.76 -5.45 -7.38 -35 -21 -17 -2.63 -14 -72
Total Depreciation and Amortization (D&A)		 -0.14 0.00 0.26 0.00 0.00 0.00 0.00 0.00 0.00 0.56 0.60
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($12,300.01) ($3,540.00) ($522.00) ($157.50) ($10.92) ($2.11) ($1.34) ($2.13) ($1.34) ($0.50) ($0.25)
Adjusted Weighted Average Basic Shares Outstanding		 6.06K 25.89K 46.81K 463.53K 6.72M 15.08M 15.48M 19.40M 27.78M 61.20M 109.05M
Adjusted Diluted Earnings per Share		 ($12,300.01) ($3,540.00) ($522.00) ($157.50) ($10.92) ($2.11) ($1.34) ($2.13) ($1.34) ($0.50) ($0.25)
Adjusted Weighted Average Diluted Shares Outstanding		 6.06K 25.89K 46.81K 463.53K 6.72M 15.08M 15.48M 19.40M 27.78M 61.20M 109.05M
Adjusted Basic & Diluted Earnings per Share		 ($12,300.01) ($3,540.00) ($522.00) ($157.50) ($10.92) ($2.11) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 5.18K 6.64K 46.81K 261.54K 2.56M 7.98M 15.91M 28.30M 56.27M 90.85M 179.58M
Normalized Net Operating Profit after Tax (NOPAT)		 -24 -11 -16 -15 -12 -12 -14 -29 -27 -22 -20
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Quarterly Metrics And Ratios for SELLAS Life Sciences Group

This table displays calculated financial ratios and metrics derived from SELLAS Life Sciences Group's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 28,347,920.00 32,062,258.00 56,267,670.00 57,754,928.00 64,332,498.00 - 90,846,692.00 99,777,487.00 105,297,469.00 142,442,239.00 179,582,574.00
DEI Adjusted Shares Outstanding		 28,347,920.00 32,062,258.00 56,267,670.00 57,754,928.00 64,332,498.00 - 90,846,692.00 99,777,487.00 105,297,469.00 142,442,239.00 179,582,574.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.33 -0.25 -0.17 -0.13 -0.11 - -0.06 -0.07 -0.06 -0.05 -0.05
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Growth		 -33.40% 11.88% 15.06% 14.27% 20.67% 17.21% 37.77% 9.82% 3.36% - -53.80%
EBIT Growth		 -31.24% 11.88% 14.49% 15.77% 21.71% 15.40% 37.14% 9.82% 3.36% - -52.60%
NOPAT Growth		 -31.00% 13.43% 14.50% 15.79% 21.71% 15.40% 37.14% 9.82% 3.36% - -52.60%
Net Income Growth		 -31.97% 10.80% 13.80% 15.50% 23.30% 17.20% 39.23% 11.63% 4.46% - -44.62%
EPS Growth		 2.94% 30.30% 55.32% 58.06% 69.70% 73.91% 66.67% 46.15% 40.00% - 28.57%
Operating Cash Flow Growth		 -19.94% 6.35% 11.26% -27.97% -13.26% -48.25% 15.71% 24.29% 9.45% - 2.47%
Free Cash Flow Firm Growth		 -284.25% -260.98% -18.44% -52.14% -3.72% -45.86% -40.94% -47.52% -46.48% - 39.78%
Invested Capital Growth		 10.79% 14.29% 18.48% 30.12% 33.65% 57.37% 91.64% 111.87% 123.10% - 129.13%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Q/Q Growth		 -3.93% 11.49% -16.27% 19.84% 3.83% 5.87% 12.61% -16.18% -3.06% - -12.32%
EBIT Q/Q Growth		 -3.46% 12.65% -17.95% 20.99% 3.83% 5.61% 12.36% -13.36% -3.06% - -12.08%
NOPAT Q/Q Growth		 -3.44% 12.65% -17.95% 20.99% 3.83% 5.61% 12.36% -13.36% -3.06% - -12.08%
Net Income Q/Q Growth		 -4.83% 12.20% -17.58% 21.91% 4.85% 5.22% 13.72% -13.56% -2.88% - -9.78%
EPS Q/Q Growth		 -6.45% 30.30% 8.70% 38.10% 23.08% 40.00% -16.67% 0.00% 14.29% - 0.00%
Operating Cash Flow Q/Q Growth		 8.91% 29.99% -123.03% 10.03% 19.38% 8.37% -26.80% 19.18% 3.57% - -79.76%
Free Cash Flow Firm Q/Q Growth		 -41.63% 0.21% -16.84% 7.87% 3.44% -40.33% -12.90% 3.57% 4.12% - 19.92%
Invested Capital Q/Q Growth		 12.89% -34.32% 16.74% 28.28% 17.29% 13.70% 83.68% 201.90% 60.90% - 121.04%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
Interest Burden Percent		 99.00% 99.50% 99.18% 98.02% 96.98% 97.38% 95.88% 96.04% 95.88% - 90.87%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Equity (ROE)		 -874.00% 2,389.76% -313.39% -888.06% -535.10% -4,147.88% -144.90% -180.71% -84.33% - -43.58%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3,472.62% -2,091.31% - -10,687.02%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Common Equity (ROCE)		 -874.00% 2,389.76% -313.39% -888.06% -535.10% -4,147.88% -144.90% -180.71% -84.33% - -43.58%
Return on Equity Simple (ROE_SIMPLE)		 1,001.44% 0.00% -369.77% 0.00% 0.00% 0.00% -97.73% 0.00% 0.00% - 0.00%
Net Operating Profit after Tax (NOPAT)		 -6.55 -5.72 -6.75 -5.33 -5.13 -4.84 -4.24 -4.81 -4.96 -5.78 -6.48
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Net Nonoperating Expense Percent (NNEP)		 -21.27% -24.30% -13.24% -18.44% -15.70% -22.80% -6.67% -10.33% -5.59% - -2.85%
Return On Investment Capital (ROIC_SIMPLE)		 - 71.76% -69.72% -183.13% -32.28% -51.16% -15.29% -18.40% -10.87% -8.15% -6.03%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings before Interest and Taxes (EBIT)		 -9.36 -8.18 -9.65 -7.62 -7.33 -6.92 -6.06 -6.87 -7.08 -8.26 -9.25
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -9.24 -8.18 -9.51 -7.62 -7.33 -6.77 -5.92 -6.87 -7.08 -8.10 -9.10
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 5.87 23.59 5.06 7.73 3.53 8.36 3.72 - 7.07
Price to Tangible Book Value (P/TBV)		 0.00 0.00 7.31 68.80 5.75 9.69 3.80 9.02 3.88 - 7.20
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 256.80 103.40 - 3,034.59
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Financial Leverage		 -2.91 6.35 -1.86 -2.99 -2.09 -11.16 -1.26 -1.19 -1.07 - -1.00
Leverage Ratio		 3.89 -8.69 2.34 4.34 2.87 17.23 1.59 1.63 1.27 - 1.10
Compound Leverage Factor		 3.85 -8.65 2.32 4.26 2.78 16.78 1.52 1.57 1.22 - 1.00
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Altman Z-Score		 -38.65 -53.85 -11.64 -19.96 -8.51 -14.22 -1.70 10.18 10.46 - 64.73
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.44 0.23 1.49 1.02 2.26 1.72 4.64 4.91 8.28 - 17.22
Quick Ratio		 0.34 0.18 1.28 0.76 1.98 1.46 4.12 4.22 7.48 - 16.59
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -7.51 -7.49 -8.75 -8.06 -7.79 -11 -12 -12 -11 -9.28 -7.43
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -7.90 -11 -8.83 -6.33 -5.24 -4.52 -0.74 0.75 1.21 -1.02 0.22
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Increase / (Decrease) in Invested Capital		 0.96 1.77 2.00 2.73 2.66 6.09 8.09 7.09 6.45 3.50 0.95
Enterprise Value (EV)		 42 31 38 59 59 59 70 193 125 - 652
Market Capitalization		 46 34 57 69 80 73 98 219 170 - 760
Book Value per Share		 ($0.14) ($0.25) $0.17 $0.05 $0.25 $0.13 $0.31 $0.26 $0.43 $0.50 $0.60
Tangible Book Value per Share		 ($0.20) ($0.31) $0.14 $0.02 $0.22 $0.11 $0.28 $0.24 $0.42 $0.48 $0.59
Total Capital		 -3.83 -7.98 9.68 2.91 16 9.47 28 26 46 71 107
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -4.07 -2.63 -19 -9.25 -21 -14 -28 -25 -44 -72 -107
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -11 -13 -11 -8.99 -7.71 -7.17 -3.41 -1.95 -1.29 -3.70 -2.48
Debt-free Net Working Capital (DFNWC)		 -6.53 -11 7.06 0.26 13 6.82 25 23 43 68 105
Net Working Capital (NWC)		 -6.53 -11 7.06 0.26 13 6.82 25 23 43 68 105
Net Nonoperating Expense (NNE)		 2.71 2.41 2.81 2.14 1.98 1.89 1.57 1.79 1.83 1.88 1.93
Net Nonoperating Obligations (NNO)		 -4.07 -2.63 -19 -9.25 -21 -14 -28 -25 -44 -72 -107
Total Depreciation and Amortization (D&A)		 0.12 0.00 0.14 0.00 0.00 0.15 0.15 0.00 0.00 0.15 0.15
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.33) ($0.23) ($0.21) ($0.13) ($0.10) ($0.06) ($0.07) ($0.07) ($0.06) ($0.05) ($0.05)
Adjusted Weighted Average Basic Shares Outstanding		 28.36M 27.78M 44.81M 57.63M 68.25M 61.20M 87.76M 98.56M 108.40M 109.05M 172.48M
Adjusted Diluted Earnings per Share		 ($0.33) ($0.23) ($0.21) ($0.13) ($0.10) ($0.06) ($0.07) ($0.07) ($0.06) ($0.05) ($0.05)
Adjusted Weighted Average Diluted Shares Outstanding		 28.36M 27.78M 44.81M 57.63M 68.25M 61.20M 87.76M 98.56M 108.40M 109.05M 172.48M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 32.06M 56.27M 57.75M 64.33M 70.38M 90.85M 99.78M 105.30M 142.44M 179.58M 186.03M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.55 -5.72 -6.75 -5.33 -5.13 -4.84 -4.24 -4.81 -4.96 -5.78 -6.48
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%

Financials Breakdown Chart

Key Financial Trends

SELLAS Life Sciences Group (NASDAQ: SLS) remains a pre-revenue biotech company with no product revenue reported across the periods provided. That means the investment story continues to hinge on clinical progress, financing access, and how long the company can fund operations before needing additional capital.

Quarterly trend summary: In Q1 2026, SELLAS reported a net loss of $8.4 million, compared with a loss of $7.7 million in Q4 2025 and $6.8 million in Q3 2025. Operating expenses rose sequentially, with R&D increasing to $5.1 million and SG&A to $4.1 million in Q1 2026. The company also continued to burn cash from operations, though it ended the quarter with a much stronger balance sheet after a large financing inflow.

Balance sheet and liquidity: SELLAS finished Q1 2026 with $107.1 million in cash and equivalents, up sharply from $44.3 million at the end of Q3 2025 and $18.4 million at the end of Q1 2025. Total assets were $114.2 million versus total liabilities of only $6.8 million, leaving the company with a solid near-term liquidity cushion. For a development-stage biotech, that cash position is the key positive takeaway from the latest quarter.

Cash flow: Operating cash burn in Q1 2026 was negative $8.8 million, which is a worsening from negative $4.9 million in Q4 2025 and negative $7.1 million in Q3 2025. The bright spot is financing: SELLAS raised $44.2 million from financing activities in Q1 2026, helping boost cash by $35.3 million during the quarter. That funding likely extends the company’s runway, but it also highlights dependence on capital markets.

  • Large cash balance: Cash and equivalents rose to $107.1 million in Q1 2026, giving SELLAS substantial short-term liquidity.
  • Strong financing buffer: The company generated $44.2 million from financing activities in Q1 2026, supporting its clinical development plans.
  • Low leverage: Total liabilities were only $6.8 million against $114.2 million in assets, leaving a very clean balance sheet.
  • Interest income contribution: SELLAS earned $845,000 in interest and investment income in Q1 2026, partially offsetting operating losses.
  • No revenue yet: The company continues to report $0 in revenue, so the business is still entirely development-stage.
  • R&D remains elevated: Research and development spending was $5.1 million in Q1 2026, indicating continued investment in pipeline programs.
  • Share count remains high: Weighted average basic shares outstanding were 172.5 million in Q1 2026, reflecting prior dilution and a large equity base.
  • Operating losses persist: SELLAS posted a net loss of $8.4 million in Q1 2026, continuing a long trend of losses.
  • Cash burn is still meaningful: Operating cash flow was negative $8.8 million in Q1 2026, suggesting the company is still consuming cash quickly.
  • Reliance on external funding: The latest cash increase was driven largely by financing rather than operations, which can pressure shareholders through dilution over time.

Bottom line: SELLAS enters the rest of 2026 with a much stronger cash position than it had a year ago, which reduces immediate balance-sheet risk. However, the company is still burning cash, has no revenue, and remains dependent on financing and clinical execution to create shareholder value.

07/13/26 10:47 PM ETAI Generated. May Contain Errors.

SELLAS Life Sciences Group Financials - Frequently Asked Questions

According to the most recent income statement we have on file, SELLAS Life Sciences Group's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

In the past 10 years, SELLAS Life Sciences Group's net income has ranged from -$63.90 million in 2015 to -$16.76 million in 2020, and is currently -$26.86 million as of their latest financial filing in 2025. Check out SELLAS Life Sciences Group's forecast to explore projected trends and price targets.

SELLAS Life Sciences Group's total operating income in 2025 was -$28.27 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $28.27 million

Over the last 10 years, SELLAS Life Sciences Group's total revenue changed from $0.00 in 2015 to $0.00 in 2025, a change of 0.0%.

SELLAS Life Sciences Group's total liabilities were at $7.47 million at the end of 2025, a 25.0% decrease from 2024, and a 89.1% decrease since 2015.

In the past 10 years, SELLAS Life Sciences Group's cash and equivalents has ranged from $2.32 million in 2017 to $71.79 million in 2025, and is currently $71.79 million as of their latest financial filing in 2025.

Over the last 10 years, SELLAS Life Sciences Group's book value per share changed from 0.08 in 2015 to 0.50 in 2025, a change of 495.8%.


Related Companies

Financial statements for NASDAQ:SLS last updated on 5/14/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel